Collegium Pharmaceutical (COLL) Stock Forecast & Price Target

Collegium Pharmaceutical is viewed positively because its pain franchise continues to generate meaningful EBITDA and free cash flow while generic risk, especially for Belbuca, appears more delayed than the market expects, preserving cash generation into the early 2030s. The company’s ADHD portfolio offers a stronger growth driver, with Jornay PM posting 41% 2Q26 revenue growth to $46.1M and Azstarys benefiting from Collegium’s 190-rep salesforce, with 2026 revenue guided to $65M–$75M. That combination supports funding for share repurchases and business development, while the expanding ADHD market and product differentiation create room for above-consensus growth.

Collegium Pharmaceutical is viewed negatively because its core pain portfolio faces structural erosion from shrinking long-acting and short-acting opioid markets, regulatory pressure, and generic competition, with Nucynta franchise net revenue already down 24% YoY to $35.2M in 2Q26 and FY2026 guidance cut by $40M. The outlook is also constrained by likely Belbuca erosion only later than the Street expects, yet still approaching a 2032 patent expiry, while the company’s growth dependence on Jornay PM and AZSTARYS is vulnerable to coverage, prior-authorization, and cost barriers that may cap adoption. Even though the stock has already fallen 50+% from its 2026 highs and trades at 5x EV/EBITDA, the long-term mix of declining opioid revenue, modest Nucynta profit-share economics, and higher spending needs supports a cautious fundamental view.